216 related articles for article (PubMed ID: 18470919)
21. An in vitro study of blood compatibility of vascular grafts made of bacterial cellulose in comparison with conventionally-used graft materials.
Fink H; Hong J; Drotz K; Risberg B; Sanchez J; Sellborn A
J Biomed Mater Res A; 2011 Apr; 97(1):52-8. PubMed ID: 21308986
[TBL] [Abstract][Full Text] [Related]
22. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
Sucker C; Zotz RB; Görlinger K; Hartmann M
Acta Anaesthesiol Scand; 2008 Mar; 52(3):358-62. PubMed ID: 18205897
[TBL] [Abstract][Full Text] [Related]
23. Assessing the in vitro biocompatibility of a novel carbon device for the treatment of sepsis.
Sandeman SR; Howell CA; Phillips GJ; Lloyd AW; Davies JG; Mikhalovsky SV; Tennison SR; Rawlinson AP; Kozynchenko OP; Owen HL; Gaylor JD; Rouse JJ; Courtney JM
Biomaterials; 2005 Dec; 26(34):7124-31. PubMed ID: 15967498
[TBL] [Abstract][Full Text] [Related]
24. Nanoporesize affects complement activation.
Ferraz N; Nilsson B; Hong J; Karlsson Ott M
J Biomed Mater Res A; 2008 Dec; 87(3):575-81. PubMed ID: 18186072
[TBL] [Abstract][Full Text] [Related]
25. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model.
Sorg H; Hoffmann JN; Menger MD; Lindenblatt N; Goehring P; Vollmar B
Thromb Haemost; 2006 Sep; 96(3):371-7. PubMed ID: 16953281
[TBL] [Abstract][Full Text] [Related]
26. Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production.
Lappegård KT; Riesenfeld J; Brekke OL; Bergseth G; Lambris JD; Mollnes TE
Ann Thorac Surg; 2005 Mar; 79(3):917-23. PubMed ID: 15734405
[TBL] [Abstract][Full Text] [Related]
27. [Complement activation in heparin--plasma inhibitory effect of anticoagulants on serum complement activation, 2nd report].
Kobayashi E; Kitano E; Kondo H; Kitamura H
Rinsho Byori; 2000 Jan; 48(1):60-6. PubMed ID: 10756677
[TBL] [Abstract][Full Text] [Related]
28. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
Wendel HP; Heller W; Gallimore MJ
Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
[TBL] [Abstract][Full Text] [Related]
29. Immobilized heparin inhibits the increase in leukocyte surface expression of adhesion molecules.
Garred P; Mollnes TE
Artif Organs; 1997 Apr; 21(4):293-9. PubMed ID: 9096801
[TBL] [Abstract][Full Text] [Related]
30. In-vitro activation of complement system by lactic acidosis in newborn and adults.
Hecke F; Hoehn T; Strauss E; Obladen M; Sonntag J
Mediators Inflamm; 2001 Feb; 10(1):27-31. PubMed ID: 11324901
[TBL] [Abstract][Full Text] [Related]
31. In vitro hemocompatibility of albumin-heparin multilayer coatings on polyethersulfone prepared by the layer-by-layer technique.
Sperling C; Houska M; Brynda E; Streller U; Werner C
J Biomed Mater Res A; 2006 Mar; 76(4):681-9. PubMed ID: 16302224
[TBL] [Abstract][Full Text] [Related]
32. Effects of immune complex formation and complement activation on circulating platelets in the primate.
Birmingham DJ; Hebert LA; Shen XP; Higgins P; Yeh CG; Creasey AA
Clin Immunol; 1999 Apr; 91(1):99-105. PubMed ID: 10219260
[TBL] [Abstract][Full Text] [Related]
33. Effect of anticoagulant on biocompatibility in membrane plasmapheresis.
Omokawa S; Malchesky PS; Yamashita M; Suzuki T; Goldcamp JG; Murabayashi S; Nosè Y
Int J Artif Organs; 1990 Nov; 13(11):768-77. PubMed ID: 2089015
[TBL] [Abstract][Full Text] [Related]
34. A functional clotting assay to monitor the hirudin dosage.
Zakir RM; Hoffman W; Bhatt BA; Spillert CR
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
[TBL] [Abstract][Full Text] [Related]
35. Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility.
Mollnes TE
Exp Clin Immunogenet; 1997; 14(1):24-9. PubMed ID: 9187920
[TBL] [Abstract][Full Text] [Related]
36. In vitro investigation of the blood response to medical grade PVC and the effect of heparin on the blood response.
Lamba NM; Courtney JM; Gaylor JD; Lowe GD
Biomaterials; 2000 Jan; 21(1):89-96. PubMed ID: 10619682
[TBL] [Abstract][Full Text] [Related]
37. Prediction of inflammatory responses induced by biomaterials in contact with human blood using protein fingerprint from plasma.
Engberg AE; Nilsson PH; Huang S; Fromell K; Hamad OA; Mollnes TE; Rosengren-Holmberg JP; Sandholm K; Teramura Y; Nicholls IA; Nilsson B; Ekdahl KN
Biomaterials; 2015 Jan; 36():55-65. PubMed ID: 25292422
[TBL] [Abstract][Full Text] [Related]
38. [The pharmacology of recombinant hirudin].
Kaiser B
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):841-9. PubMed ID: 2483701
[TBL] [Abstract][Full Text] [Related]
39. Complement activation in patients with primary antiphospholipid syndrome.
Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
[TBL] [Abstract][Full Text] [Related]
40. Effect of biologically active coating on biocompatibility of Nitinol devices designed for the closure of intra-atrial communications.
Kong X; Grabitz RG; van Oeveren W; Klee D; van Kooten TG; Freudenthal F; Qing M; von Bernuth G; Seghaye MC
Biomaterials; 2002 Apr; 23(8):1775-83. PubMed ID: 11950048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
